|
US6677158B2
|
|
Method for measurement of glycated hemoglobin by a rapid strip test procedure
|
|
US6355680B1
|
|
Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
|
|
US5994401A
|
|
In Vivo Methods to reduce hypercholesterolemia and improve vascular dysfunction
|
|
US6001875A
|
|
In vivo methods of treatment to prevent kidney dysfunction using substances that inhibit albumin glycation
|
|
WO9729746A1
|
|
Inhibition of protein glycation and prevention of vasculopathy
|
|
CA2246657A1
|
|
Inhibition of protein glycation and prevention of vasculopathy
|
|
US5908925A
|
|
Genetically engineered immunoglobulins with specificity for glycated albumin
|
|
US5518720A
|
|
Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
|
|
WO9400592A1
|
|
Monoclonal antibodies against glycated low density lipoprotein
|
|
US5312628A
|
|
Isolation of a soluble 42 KD pancreatic islet cell autoantigen
|
|
US5183739A
|
|
Monoclonal antibodies specific for non-a1c glycated hemoglobin and immunoassay methods
|
|
US5057275A
|
|
Analytic reader device
|
|
US5223392A
|
|
Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
|
